Revatio

Report
16 Pages
October 2018
Region: Global
Citeline
ID: 4775234

Drug Overview
Revatio (sildenafil; Pfizer) is a selective inhibitor of the PDE5 enzyme, which enhances the effect of the endogenous vasodilator, nitric oxide. The extracellular vasodilator NO activates cellular guanylate cyclase, which in turn increases cyclic guanosine monophosphate concentrations, leading to smooth muscle cell vasorelaxation.

Analyst Outlook
The first-to-market phosphodiesterase 5 (PDE5) inhibitor Revatio (sildenafil; Pfizer) is firmly established within the treatment algorithm as a first-line treatment for pulmonary arterial hypertension (PAH) patients. However, its loss of exclusivity in the US and EU has resulted in much-reduced sales for Pfizer. Further generic erosion in Japan is also expected from Q3 2018. Nevertheless, Revatio is likely to continue to provide a steady, albeit small, revenue stream for Pfizer, especially as physicians increasingly use combination therapies for their pulmonary hypertension (PH) patients.

OVERVIEW

Drug Overview
Product Profiles
Revatio : Pulmonary hypertension

LIST OF FIGURES

Figure 1: Revatio for pulmonary hypertension – SWOT analysis
Figure 2: The authors drug assessment summary of Revatio for pulmonary hypertension
Figure 3: The authors drug assessment summary of Revatio for pulmonary hypertension
Figure 4: Revatio sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country, 2016–25

LIST OF TABLES

Table 1: Revatio drug profile
Table 2: Revatio pivotal trial data in pulmonary hypertension
Table 3: Revatio sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country ($m), 2016–25

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€9730EUR$10,000USD£8,335GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€47676EUR$49,000USD£40,842GBP

Table of Contents

Related Topics

Related Reports

Pulmonary Arterial Hypertension Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Global Pulmonary Arterial Hypertension Market (2023-2028) Competitive Analysis, Impact of Covid-19, Impact of Economic Slowdown & Impending Recession, Ansoff Analysis

Pulmonary Arterial Hypertension Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

Global Pulmonary Arterial Hypertension Market: Analysis By Drug Class, By Type, By Route of Administration, By Distribution Channel, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2028

Pulmonary Arterial Hypertension Global Market Report 2024